Menu
Search
|

Menu

Close
X

ARCA Biopharma Inc ABIO.OQ (NASDAQ Stock Exchange Capital Market)

0.59 USD
+0.02 (+2.81%)
As of Jul 20
chart
Previous Close 0.57
Open 0.60
Volume 30,148
3m Avg Volume 77,123
Today’s High 0.60
Today’s Low 0.56
52 Week High 2.50
52 Week Low 0.45
Shares Outstanding (mil) 12.97
Market Capitalization (mil) 19.46
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.201
FY17
-1.811
FY16
-1.813
FY15
-2.256
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
--
5.73
Price to Book (MRQ)
vs sector
1.03
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
0.00
16.84
LT Debt to Equity (MRQ)
vs sector
0.00
12.51
Return on Investment (TTM)
vs sector
-82.09
14.61
Return on Equity (TTM)
vs sector
-82.23
16.34

EXECUTIVE LEADERSHIP

Robert Conway
Chairman of the Board, Since 2014
Salary: --
Bonus: --
Michael Bristow
President, Chief Executive Officer, Director, Since 2009
Salary: $279,564.00
Bonus: $21,100.00
Thomas Keuer
Chief Operating Officer, Since 2014
Salary: --
Bonus: --
Christopher Ozeroff
Senior Vice President, General Counsel, Secretary, Since 2009
Salary: $273,234.00
Bonus: $12,350.00
Brian Selby
Chief Accounting Officer, Principal Accounting Officer, Vice President - Finance, Since 2014
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

11080 Circle Point Rd Ste 140
WESTMINSTER   CO   80020-2769

Phone: +1720.9402200
Site: arcabio.com/

ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company's lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF). Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The blocking of these receptors prevents the receptor from binding with other molecules, primarily the neurotransmitter norepinephrine (NE), which activate these receptors. The Company is conducting a Phase IIB/III clinical trial of Gencaro, known as GENETIC-AF.

SPONSORED STORIES